News und Analysen
![NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b6ef578a6eaa604de21c95a83c7b989a1a3263c9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NSTG-Logo-19--28002-29.jpg?locale=de)
NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of over 125 studies enabled by
![DGAP-News: Delivery Hero schließt erfolgreich Syndizierung von Fremdfinanzierung in entsprechender Höhe von EUR 1,4 Milliarden ab: https://www.deliveryhero.com/newsroom/downloads/](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2JrS1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dbefb41b633948a96b3d6366cb1b78d9e4f5f680/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Delivery-Hero-Logo-Red.png?locale=de)
DGAP-News: Delivery Hero schließt erfolgreich Syndizierung von Fremdfinanzierung in entsprechender Höhe von EUR 1,4 Milliarden ab
![DGAP-News: Delivery Hero successfully completes syndication of EUR 1.4 billion-equivalent debt financing: https://www.deliveryhero.com/newsroom/downloads/](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2JrS1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dbefb41b633948a96b3d6366cb1b78d9e4f5f680/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Delivery-Hero-Logo-Red.png?locale=de)
DGAP-News: Delivery Hero successfully completes syndication of EUR 1.4 billion-equivalent debt financing
![Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present additional positive
![Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNElsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c4d0ef2109eb59269aca9850381b8fb5000d84e6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xencor_RGB_fullcolor.jpg?locale=de)
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
![For Canadian Mainframe Users, Cloud is the Goal: https://mms.businesswire.com/media/20210201005142/en/1016900/5/ISG_%28R%29_Logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekQ3VlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--749a83316ab9c12370626f8e1fc75f740f454d82/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ISG_-28R-29_Logo.jpg?locale=de)
For Canadian Mainframe Users, Cloud is the Goal
Mainframes are prime targets for digital transformation at many Canadian enterprises that want to increase data access, agility and automation, according to a new research report published today by
![Mainframe-to-Cloud Migration Poised to Unlock Data: https://mms.businesswire.com/media/20210201005142/en/1016900/5/ISG_%28R%29_Logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekQ3VlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--749a83316ab9c12370626f8e1fc75f740f454d82/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ISG_-28R-29_Logo.jpg?locale=de)
Mainframe-to-Cloud Migration Poised to Unlock Data
Recent advances in tools for migrating legacy applications to the cloud have altered the mainframe market, but so far, few U.S. enterprises have adopted them, according to a new research report
![LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN01qRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--21a914cdc6fc0b7ffdd18c2667f61a9a3ee0c178/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LN-Logo-Main-PANTONE.jpg?locale=de)
LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced receipt of regulatory approvals and the start of a targeted commercial launch for the
![Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlo3TEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--629850f5dff6eaa3d1fa402d0e9cf6a4216e55dd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/austin-distel-EMPZ7yRZoGw-unsplash.jpg?locale=de)
Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022
Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting
![Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTRqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8c255f1cb7b73806f677f1d1d64e93866d2979a5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Clovis_Logo_Process_Color.jpg?locale=de)
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that two abstracts featuring non-clinical data from studies evaluating FAP-2286 and Rubraca and a Trial-in-Progress poster detailing the Phase
![DGAP-HV: Evonik Industries AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2022 in Essen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
DGAP-HV: Evonik Industries AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2022 in Essen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-AGM: HUGO BOSS AG: Announcement of the Convening of the General Meeting in Bahnhofstrasse 86, 70794 Filderstadt on 24.05.2022 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
![DGAP-HV: HUGO BOSS AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.05.2022 in Bahnhofstrasse 86, 70794 Filderstadt mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
DGAP-HV: HUGO BOSS AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.05.2022 in Bahnhofstrasse 86, 70794 Filderstadt mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
![DGAP-HV: AMADEUS FIRE AG: Bekanntmachung der Einberufung zur Hauptversammlung am 19.05.2022 in Frankfurt mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
DGAP-HV: AMADEUS FIRE AG: Bekanntmachung der Einberufung zur Hauptversammlung am 19.05.2022 in Frankfurt mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
![DGAP-HV: AIXTRON SE: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2022 in Herzogenrath mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-HV: AIXTRON SE: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2022 in Herzogenrath mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
![DGAP-HV: AIXTRON SE: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2022 in Herzogenrath mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-HV: AIXTRON SE: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2022 in Herzogenrath mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
![Form 8.3 - The Vanguard Group, Inc.: NortonLifeLock Inc.http://www.icatcher.com/wp-content/uploads/2012/04/Symantec.jpg: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12176/Symantec.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdEVCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--1b3c47f309e54c35ff476143bba270ac36f5bc61/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Symantec.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: NortonLifeLock Inc.
![Form 8.3 - The Vanguard Group, Inc.: NortonLifeLock Inc.http://www.icatcher.com/wp-content/uploads/2012/04/Symantec.jpg: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12176/Symantec.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdEVCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--1b3c47f309e54c35ff476143bba270ac36f5bc61/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Symantec.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: NortonLifeLock Inc.
![Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=de)
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held